Drugs / OriC902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06891742 | Feb 2025 → Dec 2027 expected | hepatocellular carcinoma | Peking University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OriC902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891742 ↗ |
| Modality | Cell therapy | “GPC3-targeted chimeric antigen receptor autologous T cell injection” NCT06891742 ↗ |
| Target | GPC3 | “GPC3-targeted chimeric antigen receptor autologous T cell injection” NCT06891742 ↗ |